Call Us: 1.800.873.5297

By

$2.1 Million Jury Verdict Reversed in Accutane® Lawsuit

other-litigation-areasThe Switzerland-based manufacturer, Roche Holding AG, recently won a reversal of a $2.1 million jury verdict in favor of a California woman who alleged the company’s Accutane® acne medication caused her inflammatory bowel disease (IBD), Bloomberg reports.

Plaintiff Gillian Gaghan’s case went to trial in 2011, where she alleged that the company failed to warn her of the risks associated with Accutane® use. After a $2.1 million dollar jury verdict against defendants, the appellate panel reversed the verdict based on the trial judge’s error in ruling that one of the questions, whether Accutane® caused IBD, was linked to the decision by the plaintiff to ingest the drug, rather than her doctor’s decision to prescribe it.

In the 54-page appellate opinion, the panel stated that “[a] prescription drug manufacturer fulfills its duty to warn if it provides adequate warnings to the prescribing physician, and it has no duty to ensure that the warning reaches the patient.”

Accutane® was approved in the United States in 1982, but Roche pulled it off the market in 2009 after juries awarded millions of dollars to claimants alleging the medication caused them to develop IBD. Roche has faced over 8,000 lawsuits arguing that Accutane® is linked to IBD. According to the most recent report from the Judicial Panel on Multidistrict Litigation (JPML), there are currently 6 Accutane® cases left pending in the Multidistrict Litigation (MDL 1626). These MDL cases are in front of The Honorable James S. Moody, Jr. in the United States District Court for the Middle District of Florida.

 

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.